StockData
Atossa Therapeutics, Inc. logo

Atossa Therapeutics, Inc. (ATOS) stock

ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.90−0.03 (-1.55%)

Close on Nov 17, 2026Market cap $18.96MP/E –Yield –

Atossa Therapeutics cash

Cash and short-term investments held at the end of each period.

Atossa Therapeutics's cash was $26.09M at Jun 30, 2026. For fiscal 2025 it was $41.30M, down 41.9% from the year before. Over ten years it grew 27.2% a year on average. The highest annual figure on record is $136.38M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.30M-41.9%
FY2024Dec 31, 2024$71.08M-19.6%
FY2023Dec 31, 2023$88.46M-20.2%
FY2022Dec 31, 2022$110.89M-18.7%
FY2021Dec 31, 2021$136.38M+244.8%
FY2020Dec 31, 2020$39.55M+214.4%
FY2019Dec 31, 2019$12.58M+21.2%
FY2018Dec 31, 2018$10.38M+43.8%
FY2017Dec 31, 2017$7.22M+134.1%
FY2016Dec 31, 2016$3.08M-17.0%
FY2015Dec 31, 2015$3.72M-56.3%
FY2014Dec 31, 2014$8.50M+34.0%
FY2013Dec 31, 2013$6.34M+267.6%
FY2012Dec 31, 2012$1.73M-9.7%
FY2011Dec 31, 2011$1.91M+18536.7%
FY2010Dec 31, 2010$10.25K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$26.09M-54.9%
Q1 FY2026Mar 31, 2026$31.72M-51.3%
Q4 FY2025Dec 31, 2025$41.30M-41.9%
Q3 FY2025Sep 30, 2025$51.85M-30.7%
Q2 FY2025Jun 30, 2025$57.86M-27.2%
Q1 FY2025Mar 31, 2025$65.12M-22.4%
Q4 FY2024Dec 31, 2024$71.08M-19.6%
Q3 FY2024Sep 30, 2024$74.77M-20.5%
Q2 FY2024Jun 30, 2024$79.53M-20.0%
Q1 FY2024Mar 31, 2024$83.96M-19.2%
Q4 FY2023Dec 31, 2023$88.46M-20.2%
Q3 FY2023Sep 30, 2023$94.03M-19.9%
Q2 FY2023Jun 30, 2023$99.39M-20.8%
Q1 FY2023Mar 31, 2023$103.87M-21.0%
Q4 FY2022Dec 31, 2022$110.89M-18.7%
Q3 FY2022Sep 30, 2022$117.37M-16.2%
Q2 FY2022Jun 30, 2022$125.54M-11.9%
Q1 FY2022Mar 31, 2022$131.49M-4.4%
Q4 FY2021Dec 31, 2021$136.38M+244.8%
Q3 FY2021Sep 30, 2021$140.04M+1437.9%
Q2 FY2021Jun 30, 2021$142.43M+1808.6%
Q1 FY2021Mar 31, 2021$137.57M+1371.2%
Q4 FY2020Dec 31, 2020$39.55M+214.4%
Q3 FY2020Sep 30, 2020$9.11M-40.4%
Q2 FY2020Jun 30, 2020$7.46M-56.3%
Q1 FY2020Mar 31, 2020$9.35M-52.2%
Q4 FY2019Dec 31, 2019$12.58M+21.2%
Q3 FY2019Sep 30, 2019$15.29M+18.2%
Q2 FY2019Jun 30, 2019$17.06M+12.0%
Q1 FY2019Mar 31, 2019$19.57M+309.4%
Q4 FY2018Dec 31, 2018$10.38M+43.8%
Q3 FY2018Sep 30, 2018$12.94M+373.2%
Q2 FY2018Jun 30, 2018$15.24M+306.9%
Q1 FY2018Mar 31, 2018$4.78M+291.1%
Q4 FY2017Dec 31, 2017$7.22M+134.1%
Q3 FY2017Sep 30, 2017$2.73M-37.7%
Q2 FY2017Jun 30, 2017$3.75M–
Q1 FY2017Mar 31, 2017$1.22M–
Q4 FY2016Dec 31, 2016$3.08M–
Q3 FY2016Sep 30, 2016$4.39M–

More Atossa Therapeutics figures

See a number that looks wrong?